Combined corticosteroid and long-acting beta-agonist versus corticosteroid for moderate/severe chronic obstructive pulmonary disease. A double blind, randomized, multicenter, phase III study.
Phase 3
- Conditions
- COPD (Chronic obstructive pulmonary disease)Respiratory - Chronic obstructive pulmonary disease
- Registration Number
- ACTRN12609000850279
- Lead Sponsor
- Aché Laboratories
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 136
Inclusion Criteria
moderate or severe COPD according to GOLD (Global Initiative for Chronic Obstructive Lung Disease)
smoker or former smoker
Exclusion Criteria
Hospitalization due to COPD up to 4 weeks before screening visit
Subjects who have required treatment with oral corticosteroids, anti-leukotriene, immunoglobulins, beta-blockers, digitalis, itraconazole 2 months prior to Visit 1
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method